KRAS and cancer: Among them, Zn-DIGP bearing a zinc (II) cation in its structure was studied and properities of the theranostic fluorescent probe were observed with a down-regulation of c-MYC and KRAS expression in cancer lines (Figure 19, compound 37) [109,110].